This study evaluated the safety and efficacy of isoproterenol administration as an adjunct for achievement of target heart rate (HR) during dobutamine stress echocardiography (DSE).

Background

In DSE, optimal accuracy is achieved when a target HR of 85% of maximal predicted heart rate (MPHR) is attained. Although rarely studied, intravenous isoproterenol has been used as an adjunct therapy to dobutamine and atropine to increase chronotropic response during pharmacologic stress testing.

Methods

We identified 5569 DSE studies during which 264 received isoproterenol at MedStar Georgetown University Hospital from August 2011 to March 2023. Of the studies receiving isoproterenol, we collected clinical and echocardiographic parameters from each study to assess the effects of isoproterenol administration, including downstream events.

Results

In 264 examinations with isoproterenol, 169 (64%) achieved 85% MPHR. Among these, 103 (39%) developed premature ventricular contractions, 79 (30%) developed symptoms including nausea/vomiting in 44 (17%), and chest pain in 15 (6%). There was a hypertensive response to stress in 53 studies (20%) and a hypotensive response in 37 studies (14%). There was no significant increase in 30-day and 1-year death when compared to studies that did not receive isoproterenol.

Conclusions

Isoproterenol can effectively be used as an adjunctive agent in DSE to achieve the requisite hemodynamic stress for evaluation of ischemia, with a similar rate of side effects and complications compared to dobutamine and atropine stress testing.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1P. A. Pellikka, A. Arruda-Olson, F. A. Chaudhry, et al., “Guidelines for Performance, Interpretation, and Application of Stress Echocardiography in Ischemic Heart Disease: From the American Society of Echocardiography,” Journal of the American Society of Echocardiography 33, no. 1 (2020): 1–41.
10.1016/j.echo.2019.07.001
PubMed Web of Science® Google Scholar
2W. F. Armstrong and W. A. Zoghbi, “Stress Echocardiography,” Journal of the American College of Cardiology 45, no. 11 (2005): 1739–1747.
10.1016/j.jacc.2004.12.078
PubMed Web of Science® Google Scholar
3F. Lattanzi, E. Picano, E. Adamo, et al., “Dobutamine Stress Echocardiography,” Drug Safety 22, no. 4 (2000): 251–262.
10.2165/00002018-200022040-00001
CAS PubMed Web of Science® Google Scholar
4M. L. Geleijnse, B. J. Krenning, A. Nemes, et al., “Incidence, Pathophysiology, and Treatment of Complications During Dobutamine-Atropine Stress Echocardiography,” Circulation 121, no. 15 (2010): 1756–1767.
10.1161/CIRCULATIONAHA.109.859264
PubMed Web of Science® Google Scholar
5H. Murakami, H. Muto, and Y. Asano, “Efficacy and Safety of Atropine Administered Prior to Dobutamine Stress Echocardiography,” Journal of Echocardiography 5, no. 3 (2007): 65–71.
10.2303/jecho.5.65
Google Scholar
6A. J. McNeill, P. M. Fioretti, E.-S. M. El-Said, et al., “Enhanced Sensitivity for Detection of Coronary Artery Disease by Addition of Atropine to Dobutamine Stress Echocardiography,” American Journal of Cardiology 70, no. 1 (1992): 41–46.
10.1016/0002-9149(92)91387-J
CAS PubMed Web of Science® Google Scholar
7A. C. Camarozano, A. G. Siqueira-Filho, L. H. Weitzel, et al., “The Effects of Early Administration of Atropine During Dobutamine Stress Echocardiography: Advantages and Disadvantages of Early Dobutamine-Atropine Protocol,” Cardiovascular Ultrasound 4, no. 1 (2006): 17.
10.1186/1476-7120-4-17
PubMed Google Scholar
8K. McLendon and C. V. Preuss, “ Atropine. 2023 Jun 23,” StatPearls [Internet] (Treasure Island (FL): StatPearls Publishing, 2024).
Google Scholar
9S. Mraz and B. Rorabaugh, “ Dobutamine,” in xPharm: The Comprehensive Pharmacology Reference, ed. S. J. Enna and D. B. Bylund (Elsevier, 2007), 1–7.
10.1016/B978-008055232-3.61634-4
Google Scholar
10D. T. Combs and C. M. Martin, “Evaluation of Isoproterenol as a Method of Stress Testing,” American Heart Journal 87, no. 6 (1974): 711–715.
10.1016/0002-8703(74)90415-3
CAS PubMed Web of Science® Google Scholar
11R. Ajisaka, T. Fujita, and R. Matsumoto, “Isoproterenol Infusion Stress Two-Dimensional Echocardiography in Detecting Coronary Artery Disease,” Journal of Cardiography 13, no. 4 (1983): 991–1001.
CAS PubMed Google Scholar
12H. C. Hemmings and T. D. Egan, “ Vasopressors and Inotropes,” in Pharmacology and Physiology for Anesthesia - Elsevier eBook on VitalSource, 1st ed. (Elsevier Saunders, 2013).
Google Scholar
13R. M. Lang, M. Bierig, and R. B. Devereux, “Recommendations for Chamber Quantification: A Report From the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction With the European Association of Echocardiography, a Branch of the European Society of Cardiology,” Journal of the American Society of Echocardiography 18, no. 12 (2005): 1440–1463.
10.1016/j.echo.2005.10.005
PubMed Web of Science® Google Scholar
14M. W. Szymanski and D. P. Singh, “ Isoproterenol,” StatPearls (Treasure Island (FL): StatPearls Publishing, 2021).
Google Scholar
15L. I. G. Worthley, P. Tyler, and J. L. Moran, “A Comparison of Dopamine, Dobutamine and Isoproterenol in the Treatment of Shock,” Intensive Care Medicine 11, no. 1 (1985): 13–19.
10.1007/BF00256059
CAS PubMed Web of Science® Google Scholar
16H. Mertes, S. G. Sawada, T. Ryan, et al., “Symptoms, Adverse Effects, and Complications Associated With Dobutamine Stress Echocardiography. Experience in 1118 Patients,” Circulation 88, no. 1 (1993): 15–19.
10.1161/01.CIR.88.1.15
CAS PubMed Web of Science® Google Scholar
17W. Mathias Jr, A. Arruda, F. C. Santos, et al., “Safety of Dobutamine-Atropine Stress Echocardiography: A Prospective Experience of 4,033 Consecutive Studies,” Journal of the American Society of Echocardiography 12, no. 10 (1999): 785–791.
10.1016/S0894-7317(99)70182-3
PubMed Web of Science® Google Scholar
18E. Picano, W. Mathias Jr, A. Pingitore, et al., “Safety and Tolerability of Dobutamine-Atropine Stress Echocardiography: A Prospective, Multicentre Study. Echo Dobutamine International Cooperative Study Group,” Lancet 344, no. 8931 (1994): 1190–1192.
10.1016/S0140-6736(94)90508-8
CAS PubMed Web of Science® Google Scholar
19D. Poldermans, P. M. Fioretti, E. Boersma, et al., “Safety of Dobutamine-Atropine Stress Echocardiography in Patients With Suspected or Proven Coronary Artery Disease,” American Journal of Cardiology 73, no. 7 (1994): 456–459.
10.1016/0002-9149(94)90675-0
CAS PubMed Web of Science® Google Scholar
20M. A. Secknus and T. H. Marwick, “Evolution of Dobutamine Echocardiography Protocols and Indications: Safety and Side Effects in 3,011 Studies Over 5 Years,” Journal of the American College of Cardiology 29, no. 6 (1997): 1234–1240.
10.1016/S0735-1097(97)00039-9
CAS PubMed Web of Science® Google Scholar
21D. G. Katritsis, I. Karabinos, P. Papadopoulos, et al., “Sustained Ventricular Tachycardia Induced by Dobutamine Stress Echocardiography: A Prospective Study,” EP Europace 7, no. 5 (2005): 433–439.
10.1016/j.eupc.2005.05.009
PubMed Web of Science® Google Scholar

Volume42, Issue2

February 2025

e70081

Effects of Isoproterenol Administration in Dobutamine Stress Echocardiography

ABSTRACT

Objective

Background

Methods

Results

Conclusions

Conflicts of Interest

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Effects of Isoproterenol Administration in Dobutamine Stress Echocardiography

ABSTRACT

Objective

Background

Methods

Results

Conclusions

Conflicts of Interest

References

References

Related

Information